Switch to:
Also traded in: Belgium, Germany, Netherlands, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3032.04
GLPGF's Cash to Debt is ranked higher than
58% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. GLPGF: 3032.04 )
Ranked among companies with meaningful Cash to Debt only.
GLPGF' s Cash to Debt Range Over the Past 10 Years
Min: 2.96  Med: 34.81 Max: No Debt
Current: 3032.04
Equity to Asset 0.83
GLPGF's Equity to Asset is ranked higher than
72% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GLPGF: 0.83 )
Ranked among companies with meaningful Equity to Asset only.
GLPGF' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.72 Max: 0.83
Current: 0.83
0.5
0.83
Z-Score: 13.52
WACC vs ROIC
4.46%
-330.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -147.65
GLPGF's Operating margin (%) is ranked lower than
57% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -75.67 vs. GLPGF: -147.65 )
Ranked among companies with meaningful Operating margin (%) only.
GLPGF' s Operating margin (%) Range Over the Past 10 Years
Min: -147.65  Med: -26.45 Max: 1.78
Current: -147.65
-147.65
1.78
Net-margin (%) -195.46
GLPGF's Net-margin (%) is ranked lower than
61% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. GLPGF: -195.46 )
Ranked among companies with meaningful Net-margin (%) only.
GLPGF' s Net-margin (%) Range Over the Past 10 Years
Min: -195.46  Med: -12.41 Max: 47.88
Current: -195.46
-195.46
47.88
ROE (%) -41.30
GLPGF's ROE (%) is ranked lower than
57% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. GLPGF: -41.30 )
Ranked among companies with meaningful ROE (%) only.
GLPGF' s ROE (%) Range Over the Past 10 Years
Min: -41.46  Med: -9.47 Max: 17.79
Current: -41.3
-41.46
17.79
ROA (%) -35.62
GLPGF's ROA (%) is ranked lower than
58% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. GLPGF: -35.62 )
Ranked among companies with meaningful ROA (%) only.
GLPGF' s ROA (%) Range Over the Past 10 Years
Min: -33.22  Med: -6.10 Max: 11.91
Current: -35.62
-33.22
11.91
ROC (Joel Greenblatt) (%) -1255.36
GLPGF's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. GLPGF: -1255.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GLPGF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1001.81  Med: -58.01 Max: 9.71
Current: -1255.36
-1001.81
9.71
Revenue Growth (3Y)(%) -30.90
GLPGF's Revenue Growth (3Y)(%) is ranked lower than
78% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. GLPGF: -30.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GLPGF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.9  Med: 7.80 Max: 42.4
Current: -30.9
-30.9
42.4
EPS Growth (3Y)(%) 147.10
GLPGF's EPS Growth (3Y)(%) is ranked higher than
99% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. GLPGF: 147.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GLPGF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -2  Med: 18.30 Max: 147.1
Current: 147.1
-2
147.1
» GLPGF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with GLPGF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:AKBLF, OTCPK:DBVTF, NAS:AGIO, NAS:ITCI, OTCPK:AUCL, NYSE:CBM, NAS:BLUE, NAS:EXEL, NAS:NVAX, NAS:LXRX, NAS:OPHT, NAS:ARIA, NAS:RARE, OTCPK:ABCZY, NAS:PTLA, NAS:NKTR, OTCPK:PFSCF, NAS:TSRO, NAS:XLRN, NAS:ONCE » details
Traded in other countries:GLPG.Belgium, GXE.Germany, GLPG.Netherlands, 0JXZ.UK, GLPG.USA,
Galapagos NV is a a clinical stage R&D biotech that develops drugs with novel modes of action for high unmet medical needs. The Company operates in one business segment, which is R&D.

Galapagos NV was incorporated on June 30, 1999. It is a clinical-stage biotechnology company engaged in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. It has a pipeline comprising three Phase 2, three Phase 1, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company faces competition from pharmaceutical, medical device and biotechnology companies, including specialty pharmaceutical companies, and generic drug companies, academic institutions, government agencies and research institutions.

Ratios

vs
industry
vs
history
P/B 4.97
GLPGF's P/B is ranked lower than
66% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. GLPGF: 4.97 )
Ranked among companies with meaningful P/B only.
GLPGF' s P/B Range Over the Past 10 Years
Min: 2.03  Med: 4.28 Max: 7.7
Current: 4.97
2.03
7.7
P/S 52.73
GLPGF's P/S is ranked lower than
80% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 10.08 vs. GLPGF: 52.73 )
Ranked among companies with meaningful P/S only.
GLPGF' s P/S Range Over the Past 10 Years
Min: 7.71  Med: 29.02 Max: 65.57
Current: 52.73
7.71
65.57
Current Ratio 5.17
GLPGF's Current Ratio is ranked higher than
55% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. GLPGF: 5.17 )
Ranked among companies with meaningful Current Ratio only.
GLPGF' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.65 Max: 5.17
Current: 5.17
1.22
5.17
Quick Ratio 5.17
GLPGF's Quick Ratio is ranked higher than
56% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. GLPGF: 5.17 )
Ranked among companies with meaningful Quick Ratio only.
GLPGF' s Quick Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.49 Max: 5.17
Current: 5.17
1.22
5.17
Days Sales Outstanding 9.00
GLPGF's Days Sales Outstanding is ranked higher than
89% of the 611 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. GLPGF: 9.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLPGF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.05  Med: 22.12 Max: 114.23
Current: 9
7.05
114.23

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.68
GLPGF's Price/Net Cash is ranked lower than
56% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. GLPGF: 6.68 )
Ranked among companies with meaningful Price/Net Cash only.
GLPGF' s Price/Net Cash Range Over the Past 10 Years
Min: 3.81  Med: 6.06 Max: 8.31
Current: 6.68
3.81
8.31
Price/Net Current Asset Value 6.10
GLPGF's Price/Net Current Asset Value is ranked lower than
56% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. GLPGF: 6.10 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GLPGF' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.14  Med: 5.37 Max: 7.59
Current: 6.1
3.14
7.59
Price/Tangible Book 4.99
GLPGF's Price/Tangible Book is ranked lower than
57% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. GLPGF: 4.99 )
Ranked among companies with meaningful Price/Tangible Book only.
GLPGF' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.3  Med: 4.25 Max: 6.2
Current: 4.99
2.3
6.2
Price/Projected FCF 23.65
GLPGF's Price/Projected FCF is ranked lower than
99.99% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. GLPGF: 23.65 )
Ranked among companies with meaningful Price/Projected FCF only.
GLPGF' s Price/Projected FCF Range Over the Past 10 Years
Min: 7.9  Med: 7.90 Max: 7.9
Current: 23.65
Price/Median PS Value 1.82
GLPGF's Price/Median PS Value is ranked lower than
82% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 0.91 vs. GLPGF: 1.82 )
Ranked among companies with meaningful Price/Median PS Value only.
GLPGF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.3  Med: 1.29 Max: 2.27
Current: 1.82
0.3
2.27
Earnings Yield (Greenblatt) (%) -7.40
GLPGF's Earnings Yield (Greenblatt) (%) is ranked higher than
53% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. GLPGF: -7.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GLPGF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -10.1  Med: 0.80 Max: 29.75
Current: -7.4
-10.1
29.75

More Statistics

Revenue (TTM) (Mil) $70.58
EPS (TTM) $ -3.60
Beta0.17
Short Percentage of Float0.00%
52-Week Range $38.40 - 62.11
Shares Outstanding (Mil)39.08
» More Articles for GLPGF

Headlines

Articles On GuruFocus.com
The Best-Performing Non-S&P Stocks of 2015 Dec 30 2015 
Market Has Overreacted in Biogen Oct 14 2015 

More From Other Websites
Invitation to EGM and nomination of Mary Kerr for Galapagos' Board of Directors Jun 23 2016
Galapagos' R&D Update 2016 Jun 15 2016
Galapagos selected for AEX Index Jun 09 2016
FITZROY Phase 2 study with filgotinib in Crohn’s Disease presented as late breaker at DDW 2016 May 25 2016
Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA) May 24 2016
Listing of existing shares on Euronext Brussels & Amsterdam May 17 2016
Galapagos starts Phase 1 study with potentiator GLPG2451 for CF May 09 2016
Galapagos and AbbVie expand their cystic fibrosis collaboration Apr 29 2016
Galapagos kick-starts 2016 with Q1 cash position of €988 M Apr 28 2016
Galapagos reports additional data with filgotinib from the Phase 2 FITZROY study Apr 22 2016
Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients Apr 07 2016
Galapagos and MorphoSys initiate Phase 1 study in joint antibody program MOR106 Apr 07 2016
Galapagos increases share capital through warrant exercises Apr 05 2016
Publication of the annual report and invitation to the Annual Shareholders’ Meetings Mar 27 2016
Galapagos reports results with GLPG1205 in ulcerative colitis Jan 26 2016
Transparency notification - Gilead Sciences, Inc. holds 14.75% of Galapagos shares Jan 25 2016
Galapagos and Gilead complete closing of their global collaboration for filgotinib Jan 19 2016
Galapagos advances CF clinical development Jan 19 2016
Galapagos and Gilead cleared by US FTC to close their global partnership on filgotinib Jan 13 2016
Galapagos creates new warrant plan 2015 Dec 23 2015
Hedge Funds Like What They See From Cyberonics, Inc. (CYBX) Nov 23 2015
See Which of These Three Tuesday Losers Hedge Funds Say You Should Buy on the Dip Sep 29 2015
Don’t Miss White-Hot Baker Bros.’ New Healthcare Picks Aug 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)